Archive · 24 Jun 2025
New Breast Cancer Pill Shows Promise in Advancing Treatment
Scientists are excited about a new pill called Camizestrant from AstraZeneca that may help women with advanced breast cancer.
This pill could delay the need for chemotherapy and offer a more personalized treatment approach.
The drug works differently than older treatments, by blocking estrogen and stopping cancer cells from growing.
Trials show promising results, especially for those with ESR1 mutations, which can make cancer harder to treat.
Camizestrant could become a new standard of care for this type of cancer, offering a better way to manage the disease and potentially reduce side effects.
A new pill called Camizestrant, made by AstraZeneca, can delay breast cancer progression in advanced stages.
The pill could delay chemotherapy and personalize treatment if approved for use.
Camizestrant was tested in combination with a cyclin-dependent kinase (CDK) or 4/6 inhibitor in the SERENA-6 trials.
The drug blocks estrogen from binding to and activating estrogen receptors, which promotes cancer cell growth.
Camizestrant is a next-generation Selective Estrogen Receptor Degrader (SERD) being investigated for its potential effectiveness and fewer side effects.
- Who
- The pill is being developed by AstraZeneca.
- What
- Camizestrant is a new pill that can delay breast cancer progression.
- When
- The announcement came after the recently concluded phase 3 trials.
- Where
- N/A
- Why
- To provide long-term relief and potentially delay chemotherapy for women with stage 3 and 4 breast cancer.
- Drug Name
- Camizestrant
- Manufacturer
- AstraZeneca
- Trial Name
- SERENA-6
- Targeted Cancer
- HR-positive, HER2-negative advanced breast cancer
- Drug Type
- Selective Estrogen Receptor Degrader (SERD)